{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:24:41Z","timestamp":1762917881600,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Innovative Medicines Initiative Joint Undertaking","award":["115369"],"award-info":[{"award-number":["115369"]}]},{"name":"European Union\u2019s Seventh Framework Program"},{"name":"EFPIA companies\u2019"},{"name":"Institute for the Promotion of Innovation though Science and Technology in Flanders","award":["135040"],"award-info":[{"award-number":["135040"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ejpb.2018.06.025","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T19:38:40Z","timestamp":1530128320000},"page":"231-236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Linking the concentrations of itraconazole and 2-hydroxypropyl-\u03b2-cyclodextrin in human intestinal fluids after oral intake of Sporanox\u00ae"],"prefix":"10.1016","volume":"132","author":[{"given":"Philippe","family":"Berben","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jef","family":"Stappaerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias J.A.","family":"Vink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Dom\u00ednguez-Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Govert W.","family":"Somsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1478-6174","authenticated-orcid":false,"given":"Joachim","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Augustijns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2018.06.025_b0005","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.apsb.2015.07.003","article-title":"Insoluble drug delivery strategies: review of recent advances and business prospects","volume":"5","author":"Kalepu","year":"2015","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.ejpb.2018.06.025_b0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2018.06.025_b0015","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.ddtec.2011.11.006","article-title":"Overcoming poor permeability: translating permeation enhancers for oral peptide delivery","volume":"9","author":"Maher","year":"2012","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ejpb.2018.06.025_b0020","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.addr.2016.02.004","article-title":"Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials","volume":"106","author":"Aguirre","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2018.06.025_b0025","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/pr.112.005660","article-title":"Strategies to address low drug solubility in discovery and development","volume":"65","author":"Williams","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejpb.2018.06.025_b0030","first-page":"300","article-title":"PBPK models for the prediction of in vivo performance of oral dosage forms","volume":"57","author":"Kostewicz","year":"2014","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.06.025_b0035","first-page":"342","article-title":"In vitro models for the prediction of in vivo performance of oral dosage forms","volume":"57","author":"Kostewicz","year":"2014","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.06.025_b0040","first-page":"292","article-title":"Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo","volume":"57","author":"Lennern\u00e4s","year":"2014","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.06.025_b0045","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1080\/10717544.2016.1214990","article-title":"Controversies with self-emulsifying drug delivery system from pharmacokinetic point of view","volume":"23","author":"Chatterjee","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2018.06.025_b0050","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1002\/jps.22550","article-title":"PHRMA CPCDC initiative on predictive models of human pharmacokinetics, Part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach","volume":"100","author":"Poulin","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.06.025_b0055","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijpharm.2016.11.063","article-title":"Exploring gastrointestinal variables affecting drug and formulation behavior: methodologies, challenges and opportunities","volume":"519","author":"Hens","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2018.06.025_b0060","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/jps.24603","article-title":"Characterization of human duodenal fluids in fasted and fed state conditions","volume":"105","author":"Riethorst","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.06.025_b0065","first-page":"2","article-title":"Resolving intraluminal drug and formulation behavior: gastrointestinal concentration profiling in humans","volume":"61","author":"Brouwers","year":"2014","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.06.025_b0070","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejpb.2016.10.027","article-title":"Exploring the link between gastric motility and intragastric drug distribution in man","volume":"112","author":"Van Den Abeele","year":"2017","journal-title":"Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Pharm. Verfahrenstechnik EV"},{"key":"10.1016\/j.ejpb.2018.06.025_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2015.01.001","article-title":"Rapid conversion of the ester prodrug abiraterone acetate results in intestinal supersaturation and enhanced absorption of abiraterone: in vitro, rat in situ and human in vivo studies","volume":"90","author":"Stappaerts","year":"2015","journal-title":"Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Pharm. Verfahrenstechnik EV"},{"key":"10.1016\/j.ejpb.2018.06.025_b0080","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/jps.20553","article-title":"Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: a case study with amprenavir","volume":"95","author":"Brouwers","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.06.025_b0085","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijpharm.2017.04.057","article-title":"Gastrointestinal behavior of itraconazole in humans - Part 2: the effect of intraluminal dilution on the performance of a cyclodextrin-based solution","volume":"526","author":"Berben","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2018.06.025_b0090","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0378-5173(98)00393-7","article-title":"Characterization of itraconazole\/2-hydroxypropyl-beta-cyclodextrin inclusion complex in aqueous propylene glycol solution","volume":"179","author":"Miyake","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2018.06.025_b0095","first-page":"94","article-title":"Comparative interaction of 2-hydroxypropyl-beta-cyclodextrin and sulfobutylether-beta-cyclodextrin with itraconazole: phase-solubility behavior and stabilization of supersaturated drug solutions","volume":"34","author":"Brewster","year":"2008","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.06.025_b0100","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ijpharm.2016.07.063","article-title":"Displacement of itraconazole from cyclodextrin complexes in biorelevant media: in vitro evaluation of supersaturation and precipitation behavior","volume":"511","author":"Stappaerts","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2018.06.025_b0105","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijpharm.2017.04.029","article-title":"Gastrointestinal behavior of itraconazole in humans - Part 1: supersaturation from a solid dispersion and a cyclodextrin-based solution","volume":"525","author":"Brouwers","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2018.06.025_b0110","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/jps.10126","article-title":"Characterization of the interaction of 2-hydroxypropyl-\u03b2-cyclodextrin with itraconazole at pH 2, 4, and 7","volume":"91","author":"Peeters","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.06.025_b0115","first-page":"217","article-title":"Supersaturating drug delivery systems: effect of hydrophilic cyclodextrins and other excipients on the formation and stabilization of supersaturated drug solutions","volume":"63","author":"Brewster","year":"2008","journal-title":"Pharmazie"},{"key":"10.1016\/j.ejpb.2018.06.025_b0120","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1021\/js960213f","article-title":"Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation","volume":"86","author":"Irie","year":"1997","journal-title":"J. Pharm. Sci."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641118300109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641118300109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:31:44Z","timestamp":1760545904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641118300109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":24,"alternative-id":["S0939641118300109"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2018.06.025","relation":{},"ISSN":["0939-6411"],"issn-type":[{"type":"print","value":"0939-6411"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Linking the concentrations of itraconazole and 2-hydroxypropyl-\u03b2-cyclodextrin in human intestinal fluids after oral intake of Sporanox\u00ae","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2018.06.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}